**Supplementary Table 1: Proteins extracted from references**

|  |  |  |  |
| --- | --- | --- | --- |
| Uniprot ACCs | Gene Names | Description | Reference |
| O00716 | E2F3 | E2F transcription factor 3 | [1] |
| O00762 | UBE2C | Ubiquitin-conjugating enzyme E2C | [2] |
| O43399 | TPD52L2 | Tumor protein D52-like 2 | [3] |
| O43915 | FIGF | C-fos induced growth factor (vascular endothelial growth factor D) | [4] |
| P01116 | KRAS | V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | [5] |
| P04626 | ERBB2 | V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | [6, 7] |
| P05451 | REG1A | Regenerating islet-derived 1 alpha | [8] |
| P07737 | PFN1 | Profilin 1 | [9] |
| P04637 | TP53 | Cellular tumor antigen p53 | [10, 11] |
| P07992 | ERCC1 | Excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence) | [12] |
| P08069 | IGF1R | Insulin-like growth factor 1 receptor | [13] |
| P08581 | MET | Met proto-oncogene (hepatocyte growth factor receptor) | [14] |
| P09429 | HMGB1 | High-mobility group box 1 | [15] |
| P10145 | CXCL8 | Interleukin 8 | 39 |
| P10635 | CYP2D6 | Cytochrome P450, family 2, subfamily D, polypeptide 6 | [16] |
| P14210 | HGF | Hepatocyte growth factor (hepapoietin A; scatter factor) | [14] |
| P14780 | MMP9 | Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) | [17, 18] |
| P16070 | CD44 | CD44 molecule (Indian blood group) | [19] |
| P16220 | CREB1 | CAMP responsive element binding protein 1 | [20] |
| P20248 | CCNA2 | Cyclin A2 | [1] |
| P21926 | CD9 | CD9 molecule | [21] |
| P24941 | CDK2 | Cyclin-dependent kinase 2 | [1] |
| P27695 | APEX1 | APEX nuclease (multifunctional DNA repair enzyme) 1 | [22] |
| P29350 | PTPN6 | Protein tyrosine phosphatase, non-receptor type 6 | [23] |
| P30990 | NTS | Neurotensin | [17] |
| P31749 | AKT1 | V-akt murine thymoma viral oncogene homolog 1 | [24, 25] |
| P31751 | AKT2 | V-akt murine thymoma viral oncogene homolog 2 | [26] |
| P35716 | SOX11 | SRY (sex determining region Y)-box 11 | [3] |
| P37059 | HSD17B2 | Hydroxysteroid (17-beta) dehydrogenase 2 | [27] |
| P37275 | ZEB1 | Zinc finger E-box binding homeobox 1 | [28, 29] |
| P41221 | WNT5A | Wingless-type MMTV integration site family, member 5A | [30] |
| P42336 | PIK3CA | Phosphoinositide-3-kinase, catalytic, alpha polypeptide | [5, 26, 31] |
| P42345 | MTOR | FK506 binding protein 12-rapamycin associated protein 1 | [4, 31] |
| P46013 | MKI67 | Antigen identified by monoclonal antibody Ki-67 | [10] |
| P46527 | CDKN1B | Cyclin-dependent kinase inhibitor 1B (p27, Kip1) | [10] |
| P46531 | NOTCH1 | Notch homolog 1, translocation-associated (Drosophila) | [25, 32, 33] |
| P49767 | VEGFC | Vascular endothelial growth factor C | [4] |
| P50281 | MMP14 | Matrix metallopeptidase 14 (membrane-inserted) | [34] |
| P50616 | TOB1 | Transducer of ERBB2, 1 | [7] |
| P51679 | CCR4 | Chemokine (C-C motif) receptor 4 | [7] |
| P60484 | PTEN | Phosphatase and tensin homolog | [25, 33] |
| P61586 | RHOA | Ras homolog gene family, member A | [35] |
| P78536 | ADAM17 | ADAM metallopeptidase domain 17 | [36] |
| P98177 | FOXO4 | Forkhead box O4 | [37] |
| Q00534 | CDK6 | Cyclin-dependent kinase 6 | [1] |
| Q00653 | NFKB2 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) | [38] |
| Q03135 | CAV1 | Caveolin 1, caveolae protein, 22kDa | [30] |
| Q12778 | FOXO1 | Forkhead box O1 | [39] |
| Q12829 | RAB40B | RAB40B, member RAS oncogene family | [40] |
| Q13153 | PAK1 | P21 protein (Cdc42/Rac)-activated kinase 1 | [40] |
| Q13283 | G3BP1 | GTPase activating protein (SH3 domain) binding protein 1 | [41] |
| Q13761 | RUNX3 | Runt-related transcription factor 3 | [42-44] |
| Q14511 | NEDD9 | Neural precursor cell expressed, developmentally down-regulated 9 | [20] |
| Q15063 | POSTN | Periostin, osteoblast specific factor | [45] |
| Q15554 | TERF2 | Telomeric repeat binding factor 2 | [37] |
| Q15672 | TWIST1 | Twist-related protein 1 | [46] |
| Q16665 | HIF1A | Hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | [39] |
| Q6VUC0 | TFAP2E | Transcription factor AP-2 epsilon (activating enhancer binding protein 2 epsilon) | [47] |
| Q7L099 | RUFY3 | RUN and FYVE domain containing 3 | [40] |
| Q8NF37 | LPCAT1 | Lysophosphatidylcholine acyltransferase 1 | [48] |
| Q92743 | HTRA1 | HtrA serine peptidase 1 | [49] |
| Q96EB6 | SIRT1 | NAD-dependent protein deacetylase sirtuin-1 | [39] |
| Q99626 | CDX2 | Caudal type homeobox 2 | [50] |
| Q9GZV4 | EIF5A2 | Eukaryotic translation initiation factor 5A2 | [51] |
| Q9HBM0 | VEZT | Vezatin, adherens junctions transmembrane protein | [52] |
| Q9NRD0 | FBXO8 | F-box protein 8 | [53] |
| Q9NS71 | GKN1 | Gastrokine 1 | [54, 55] |
| Q9NYB0 | TERF2IP | Telomeric repeat binding factor 2, interacting protein | [37] |
| Q9NZQ7 | CD274 | CD274 molecule | [22] |
| Q9UII2 | ATPIF1 | ATPase inhibitory factor 1 | [56] |
| Q9Y251 | HPSE | Heparanase | [14] |
| Q9Y6X2 | PIAS3 | Protein inhibitor of activated STAT, 3 | [57] |

**Reference**

[1] S. Chang, L. Gao, Y. Yang, D. Tong, B. Guo, L. Liu, Z. Li, T. Song, C. Huang, miR-145 mediates the antiproliferative and gene regulatory effects of vitamin D3 by directly targeting E2F3 in gastric cancer cells, Oncotarget, 6 (2015) 7675-7685.

[2] Y. Zhang, T. Han, G. Wei, Y. Wang, Inhibition of microRNA-17/20a suppresses cell proliferation in gastric cancer by modulating UBE2C expression, Oncology reports, 33 (2015) 2529-2536.

[3] J. Xu, W. Wang, Z. Zhu, Z. Wei, D. Yang, Q. Cai, Tumor Protein D52-Like 2 Accelerates Gastric Cancer Cell Proliferation In Vitro, Cancer Biotherapy and Radiopharmaceuticals, 30 (2015) 111-116.

[4] H. Chen, R. Guan, Y. Lei, J. Chen, Q. Ge, X. Zhang, R. Dou, H. Chen, H. Liu, X. Qi, Lymphangiogenesis in Gastric Cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis, BMC cancer, 15 (2015) 103.

[5] W. Lu, H. Wei, M. Li, H. Wang, L. Liu, Q. Zhang, L. Liu, S. Lu, Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer, Molecular medicine reports, 12 (2015) 1219-1224.

[6] J. Rüschoff, W. Hanna, M. Bilous, M. Hofmann, R.Y. Osamura, F. Penault-Llorca, M. van de Vijver, G. Viale, HER2 testing in gastric cancer: a practical approach, Modern Pathology, 25 (2012) 637-650.

[7] S.Q. Zhang, K.K. Sun, X.Y. Wu, N. Zhong, H. Zhao, D.C. Li, Clinicopathological significance of cytoplasmic transducer of ErbB2. 1 expression in gastric cancer, Molecular medicine reports, 12 (2015) 1177-1182.

[8] K. Hara, H. Fukui, C. Sun, Y. Kitayama, H. Eda, T. Yamasaki, T. Kondo, T. Tomita, T. Oshima, J. Watari, Effect of REG Iα protein on angiogenesis in gastric cancer tissues, Oncology reports, 33 (2015) 2183-2189.

[9] Y.-J. Cheng, Z.-X. Zhu, J.-S. Zhou, Z.-Q. Hu, J.-P. Zhang, Q.-P. Cai, L.-H. Wang, Silencing profilin-1 inhibits gastric cancer progression via integrin β1/focal adhesion kinase pathway modulation, World journal of gastroenterology: WJG, 21 (2015) 2323.

[10] M. Calik, E. Demirci, E. Altun, I. Calik, Clinicopathological importance of Ki-67, p27, and p53 expression in gastric cancer, Turkish journal of medical sciences, 45 (2015) 118-128.

[11] P.A. Muller, K.H. Vousden, Mutant p53 in cancer: new functions and therapeutic opportunities, Cancer cell, 25 (2014) 304-317.

[12] P. Song, Q. Yin, M. Lu, B. Fu, B. Wang, Q. Zhao, Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis, Experimental and therapeutic medicine, 9 (2015) 1393-1400.

[13] Y. Gong, J. Ren, K. Liu, L.-M. Tang, Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R, World journal of gastroenterology: WJG, 21 (2015) 2949.

[14] N.-B. Hao, B. Tang, G.-Z. Wang, R. Xie, C.-J. Hu, S.-M. Wang, Y.-Y. Wu, E. Liu, X. Xie, S.-M. Yang, Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K/Akt/NF-κB signaling pathway for gastric cancer metastasis, Cancer letters, 361 (2015) 57-66.

[15] H.W. Chung, S. Jang, H. Kim, J.B. Lim, Combined targeting of high‐mobility group box‐1 and interleukin‐8 to control micrometastasis potential in gastric cancer, International Journal of Cancer, (2015).

[16] S.-B. Wu, L.-N. Cai, X.-H. Yang, H.-G. Fu, K. Sun, F. Yuan, T.-L. Dong, Impact of CYP2D6 Polymorphisms on Postoperative Fentanyl Analgesia in Gastric Cancer Patients, Genetic testing and molecular biomarkers, 19 (2015) 248-252.

[17] H. Akter, M. Park, O.-S. Kwon, E.J. Song, W.-S. Park, M.-J. Kang, Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer, Tumor Biology, (2015) 1-10.

[18] J. Chen, X. Liu, H. Jiao, L. Peng, Z. Huo, W. Yang, Q. Shen, T. Li, Q. Liu, Prognostic and clinical significance of STAT3 and MMP9 in patients with gastric cancer: a meta-analysis of a Chinese cohort, International journal of clinical and experimental medicine, 8 (2015) 546.

[19] J.-W. Xie, P.-C. Chen, C.-H. Zheng, P. Li, J.-B. Wang, J.-X. Lin, J. Lu, Q.-Y. Chen, L.-L. Cao, M. Lin, Evaluation of the prognostic value and functional roles of CD44v6 in gastric cancer, Journal of cancer research and clinical oncology, (2015) 1-9.

[20] Y.-W. Wang, X. Chen, J.-W. Gao, H. Zhang, R.-R. Ma, Z.-H. Gao, P. Gao, High expression of cAMP-responsive element-binding protein 1 (CREB1) is associated with metastasis, tumor stage and poor outcome in gastric cancer, Oncotarget, (2015).

[21] Y. Murayama, K. Oritani, S. Tsutsui, Novel CD9-targeted therapies in gastric cancer, World journal of gastroenterology: WJG, 21 (2015) 3206.

[22] Y. Qing, Q. Li, T. Ren, W. Xia, Y. Peng, G.-L. Liu, H. Luo, Y.-X. Yang, X.-Y. Dai, S.-F. Zhou, Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer, Drug design, development and therapy, 9 (2015) 901.

[23] M.K. Joo, J.J. Park, S.H. Kim, H.S. Yoo, B.J. Lee, H.J. Chun, S.W. Lee, Y.T. Bak, Antitumorigenic effect of plumbagin by induction of SH2‑containing protein tyrosine phosphatase 1 in human gastric cancer cells, International journal of oncology, 46 (2015) 2380-2388.

[24] L.P. Nacusi, R.J. Sheaff, Akt1 sequentially phosphorylates p27kip1 within a conserved but non-canonical region, Cell division, 1 (2006) 11.

[25] W. Zhou, X. Fu, L. Zhang, J. Zhang, X. Huang, X. Lu, L. Shen, B. Liu, J. Liu, H. Luo, The AKT1/NF-kappaB/Notch1/PTEN axis has an important role in chemoresistance of gastric cancer cells, Cell death & disease, 4 (2013) e847.

[26] Q.-Y. Zhang, W.-X. Cheng, W.-M. Li, W. Au, Y.-Y. Lu, Occurrence of low frequency PIK3CA and AKT2 mutations in gastric cancer, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 769 (2014) 108-112.

[27] B.A. Frycz, D. Murawa, M. Borejsza-Wysocki, R. Marciniak, P. Murawa, M. Drews, P.P. Jagodziński, Expression of 17β-hydroxysteroid dehydrogenase type 2 is associated with some clinicopathological features in gastric cancer, Biomedicine & Pharmacotherapy, 70 (2015) 24-27.

[28] N. Yabusaki, S. Yamada, T. Murai, M. Kanda, D. Kobayashi, C. Tanaka, T. Fujii, G. Nakayama, H. Sugimoto, M. Koike, Clinical significance of zinc-finger E-box binding homeobox 1 mRNA levels in peritoneal washing for gastric cancer, Molecular and clinical oncology, 3 (2015) 435-441.

[29] Y. Okugawa, Y. Toiyama, K. Tanaka, K. Matsusita, H. Fujikawa, S. Saigusa, M. Ohi, Y. Inoue, Y. Mohri, K. Uchida, Clinical significance of zinc finger E‐box binding homeobox 1 (ZEB1) in human gastric cancer, Journal of surgical oncology, 106 (2012) 280-285.

[30] X.-J. Shen, H. Zhang, G.-S. Tang, X.-D. Wang, R. Zheng, Y. Wang, Y. Zhu, X.-C. Xue, J.-W. Bi, Caveolin-1 is a Modulator of Fibroblast Activation and a Potential Biomarker for Gastric Cancer, International journal of biological sciences, 11 (2015) 370.

[31] J.H. Park, M.-H. Ryu, Y.S. Park, S.R. Park, Y.-S. Na, B.-Y. Rhoo, Y.-K. Kang, Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression, BMC cancer, 15 (2015) 119.

[32] Q. Hang, R. Sun, C. Jiang, Y. Li, Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression, Anti-cancer drugs, 26 (2015) 632-640.

[33] S. Kim, H. Lee, J. Baek, Y. Cho, H. Kang, J. Jeong, J. Song, H. Park, K. Chun, Activation of nuclear PTEN by inhibition of Notch signaling induces G2/M cell cycle arrest in gastric cancer, Oncogene, (2015).

[34] Y. Dong, G. Chen, M. Gao, X. Tian, Increased expression of MMP14 correlates with the poor prognosis of Chinese patients with gastric cancer, Gene, 563 (2015) 29-34.

[35] T. Ushiku, S. Ishikawa, M. Kakiuchi, A. Tanaka, H. Katoh, H. Aburatani, G.Y. Lauwers, M. Fukayama, RHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases, Gastric Cancer, (2015) 1-9.

[36] D. Aydin, A. Bilici, D. Yavuzer, U. Kefeli, A. Tan, O. Ercelep, A. Mert, S. Yuksel, M. Ozcelik, D. Isik, Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy, Clinical and Translational Oncology, (2015) 1-8.

[37] X. Li, W. Liu, H. Wang, L. Yang, Y. Li, H. Wen, H. Ning, J. Wang, L. Zhang, J. Li, Rap1 is indispensable for TRF2 function in etoposide-induced DNA damage response in gastric cancer cell line, Oncogenesis, 4 (2015) e144.

[38] K.A. Manu, M.K. Shanmugam, L. Ramachandran, F. Li, K.S. Siveen, A. Chinnathambi, M. Zayed, S.A. Alharbi, F. Arfuso, A.P. Kumar, Isorhamnetin augments the anti-tumor effect of capeciatbine through the negative regulation of NF-κB signaling cascade in gastric cancer, Cancer letters, 363 (2015) 28-36.

[39] S.Y. Kim, Y.S. Ko, J. Park, Y. Choi, J.-W. Park, Y. Kim, J.-S. Pyo, Y.B. Yoo, J.-S. Lee, B.L. Lee, Forkhead Transcription Factor FOXO1 Inhibits Angiogenesis in Gastric Cancer in Relation to SIRT1, Cancer Research and Treatment, (2015).

[40] G. Wang, Q. Zhang, Y. Song, X. Wang, Q. Guo, J. Zhang, J. Li, Y. Han, Z. Miao, F. Li, PAK1 regulates RUFY3-mediated gastric cancer cell migration and invasion, Cell death & disease, 6 (2015) e1682.

[41] L. Min, Y. Ruan, Z. Shen, D. Jia, X. Wang, J. Zhao, Y. Sun, J. Gu, Overexpression of Ras‐GTPase‐activating protein SH3 domain‐binding protein 1 correlates with poor prognosis in gastric cancer patients, Histopathology, (2015).

[42] Z. Liu, X. Zhang, X. Xu, L. Chen, W. Li, H. Yu, Y. Sun, J. Zeng, J. Jia, RUNX3 inhibits survivin expression and induces cell apoptosis in gastric cancer, European journal of cell biology, 93 (2014) 118-126.

[43] G. Keller, H. Vogelsang, I. Becker, S. Plaschke, K. Ott, G. Suriano, A. Mateus, R. Seruca, K. Biedermann, D. Huntsman, Germline mutations of the E-cadherin (CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients, Journal of medical genetics, 41 (2004) e89-e89.

[44] H. Fukamachi, K. Ito, Growth regulation of gastric epithelial cells by Runx3, Oncogene, 23 (2004) 4330-4335.

[45] G.-X. Liu, H.-Q. Xi, X.-Y. Sun, B. Wei, Role of periostin and its antagonist PNDA-3 in gastric cancer metastasis, World journal of gastroenterology: WJG, 21 (2015) 2605.

[46] H. Zhang, J. Gong, D. Kong, H.-Y. Liu, Anti-proliferation effects of Twist gene silencing in gastric cancer SGC7901 cells, World journal of gastroenterology: WJG, 21 (2015) 2926.

[47] J. Sun, N. Du, J. Li, J. Zhou, G. Tao, S. Sun, J. He, Transcription Factor AP2∊ A Potential Predictor of Chemoresistance in Patients With Gastric Cancer, Technology in cancer research & treatment, (2015) 1533034615577028.

[48] T. Uehara, H. Kikuchi, S. Miyazaki, I. Iino, T. Setoguchi, Y. Hiramatsu, M. Ohta, K. Kamiya, Y. Morita, H. Tanaka, Overexpression of Lysophosphatidylcholine Acyltransferase 1 and Concomitant Lipid Alterations in Gastric Cancer, Annals of surgical oncology, (2015) 1-8.

[49] Z. Zhao, H. Li, C. Wang, W. Xu, J. Sun, W. Zhao, Serine protease HtrA1 as an inhibitor on proliferation invasion and migration of gastric cancer, Medical Oncology, 32 (2015) 1-7.

[50] W. Wei, L. Li, X. Wang, L. Yan, W. Cao, Z. Zhan, X. Zhang, H. Yu, Y. Xie, Q. Xiao, Overexpression of caudal type homeobox transcription factor 2 inhibits the growth of the MGC‑803 human gastric cancer cell line in vivo, Molecular medicine reports, 12 (2015) 905-912.

[51] Q.-B. Meng, W.-M. Kang, J.-C. Yu, Y.-Q. Liu, Z.-Q. Ma, L. Zhou, Q.-C. Cui, W.-X. Zhou, Overexpression of Eukaryotic Translation Initiation Factor 5A2 (EIF5A2) Correlates with Cell Aggressiveness and Poor Survival in Gastric Cancer, PloS one, 10 (2015).

[52] G.-J. Wang, G.-H. Liu, Y.-W. Ye, Y. Fu, X.-F. Zhang, The role of microRNA-1274a in the tumorigenesis of gastric cancer: Accelerating cancer cell proliferation and migration via directly targeting FOXO4, Biochemical and biophysical research communications, 459 (2015) 629-635.

[53] P. Wu, F. Wang, Y. Wang, H. Men, X. Zhu, G. He, W. Ma, S. Xin, J. Wu, W. Liao, Significance of FBX8 in progression of gastric cancer, Experimental and molecular pathology, 98 (2015) 360-366.

[54] R. Xing, W.-M. Li, J.-T. Cui, N. Xia, Y.-Y. Lu, GKN1 Inhibits Cell Invasion in Gastric Cancer by Inactivating the NF-kappaB Pathway, Discovery medicine, 19 (2015) 65-71.

[55] B.J. Choi, J.H. Yoon, W.S. Choi, O. Kim, S.W. Nam, J.Y. Lee, W.S. Park, GKN1 and miR-185 are associated with CpG island methylator phenotype in gastric cancers, Molecular & Cellular Toxicology, 9 (2013) 227-233.

[56] T. Yin, L. Lu, Z. Xiong, S. Wei, D. Cui, ATPase inhibitory factor 1 is a prognostic marker and contributes to proliferation and invasion of human gastric cancer cells, Biomedicine & Pharmacotherapy, 70 (2015) 90-96.

[57] J. Li, J. Cui, J. Zhang, Y. Liu, L. Han, C. Jia, J. Deng, H. Liang, PIAS3, an inhibitor of STAT3, has intensively negative association with the survival of gastric cancer, International journal of clinical and experimental medicine, 8 (2015) 682.